UNSPSC 51292103: Litracen

This classification denotes an antidepressant agent with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B3D399IVR, chemically known as 9-(3-methylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene. but generally known as litracen, which bears US NIH Compound Identifier 82730. European Medicines Agency schedules Litracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08537MIG. The term LITRACEN is an International Non-Proprietary Name.

UNSPSC 51292103 Litracen, a Commodity code, covers pharmaceutical products — specifically naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications — that state and local health agencies, cooperative purchasing organizations, and community health programs procure to support substance-abuse response, emergency medical services, and public health initiatives. State and local solicitations under this code include county health departments, state HHS commissions, and multi-state cooperative purchasing alliances. The work involves competitive bidding for pharmaceutical supply contracts with requirements for cGMP and Drug Supply Chain Security Act compliance, wholesaler partnerships, electronic data interchange capability, insurance coverage, and E-Verify employment eligibility verification.

Recent activity spans multiple states and regions. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026 and contract effectiveness July 1, 2026; MMCAP evaluates on price competitiveness (75 percent weight), fixed pricing, EDI capability, administrative fee compliance, and data format requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and wholesaler arrangements. Bidders should expect to submit detailed product information by National Drug Code, maintain relationships with authorized wholesalers or manufacturers, demonstrate pricing flexibility across multiple formats, and carry substantial insurance coverage including commercial general liability of $2 million to $5 million.